New heart catheter aims to zap Hard-to-Treat AFib
NCT ID NCT06960252
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new catheter called OPTRELL™ to map and treat persistent atrial fibrillation (AF), a type of irregular heartbeat that is harder to treat. The device helps doctors identify and target the specific areas in the heart causing the problem. The trial will enroll 80 people with persistent AF to see if this approach reduces the chance of the arrhythmia returning after ablation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OPTRELL™ Mapping Catheter (a device used to map the heart's electrical signals during ablation)
What this could lead to
If successful, this could improve the precision of ablation for persistent atrial fibrillation, potentially reducing the chance of the arrhythmia coming back.
What could go wrong
This is a small, early-stage study (80 participants) testing a new device. The approach may not work better than standard ablation, and there are always risks with heart procedures like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Outside US, 112, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••